Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 160 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Teen Helps Mom With Cancer Shave Her Head, Then Turns To... October 1, 2021 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 New on NCI’s Websites for October 2019 October 3, 2019 Load more HOT NEWS 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... MGUS to Myeloma: Study Suggests Risk of Progression Can Change EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma
